COVID-19 mRNA LNP vaccine - Precision Nanosystems/Tianjin CanSino Biotechnology
Alternative Names: COVID-19 RNA vaccine; COVID-19-mRNA-LNP vaccineLatest Information Update: 28 Jun 2024
At a glance
- Originator Precision NanoSystems; Tianjin CanSino Biotechnology
- Class COVID-19 vaccines; RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 06 Jul 2022 Phase-II clinical trials in COVID-2019 infections (Prevention, In adults, In the elderly) in China (Parenteral) (NCT05373472)
- 20 May 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in China (Parenteral) (NCT05373485)